Local effect of stereotactic body radiotherapy for primary and metastatic liver tumors in 130 Japanese patients

Radiation Oncology

Volumn 9, Issue 1, 2014, Pages

  Yamashita, Hideomi ^a   Onishi, Hiroshi ^b   Matsumoto, Yasuo ^c   Murakami, Naoya ^d   Matsuo, Yukinori ^e   Nomiya, Takuma ^f   Nakagawa, Keiichi ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b UNIVERSITY OF YAMANASHI   (Japan)

^c NIIGATA CANCER CENTER HOSPITAL   (Japan)

^d DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^e KYOTO UNIVERSITY   (Japan)

^f YAMAGATA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Hepatocellular carcinoma; Metastatic liver tumor; Stereotactic ablative radiotherapy; Stereotactic body radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PACLITAXEL; TS 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTERY RUPTURE; ARTICLE; BILE DUCT CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CHEMOEMBOLIZATION; CHEMORADIOTHERAPY; COLON CANCER; DUODENUM ULCER; FEMALE; FOLLOW UP; GASTRITIS; GASTROINTESTINAL TOXICITY; HUMAN; INTESTINAL BLEEDING; INTESTINE ULCER; JAPANESE (PEOPLE); LIVER CELL CARCINOMA; LIVER METASTASIS; LOCAL THERAPY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PANCREAS CANCER; PRIMARY TUMOR; RADIATION RESPONSE; RECTUM CANCER; RETROSPECTIVE STUDY; SKIN CANCER; STEREOTACTIC BODY RADIATION THERAPY; STOMACH CANCER; STOMACH ULCER; THORAX PAIN; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; UTERINE CERVIX CANCER; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; PATHOLOGY; PROGNOSIS; RADIOSURGERY; SECONDARY; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS; PROGNOSIS; RADIOSURGERY; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84901280168     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-9-112     Document Type: Article

References (40)

1. Arii S, Sata M, Sakamoto M, Shimada M, Kumada T, Shiina S, Yamashita T, Kokudo N, Tanaka M, Takayama T, Kudo M. Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res 2010, 40:667-685. 10.1111/j.1872-034X.2010.00673.x, 20633193.
2. Yamashita H, Nakagawa K, Shiraishi K, Tago M, Igaki H, Nakamura N, Sasano N, Siina S, Omata M, Ohtomo K. Radiotherapy for lymph node metastases in patients with hepatocellular carcinoma: retrospective study. J Gastroenterol Hepatol 2007, 22:523-527. 10.1111/j.1440-1746.2006.04450.x, 17376045.
3. Garrean S, Hering J, Saied A, Helton WS, Espat NJ. Radiofrequency ablation of primary and metastatic liver tumors: a critical review of the literature. Am J Surg 2008, 195:508-520. 10.1016/j.amjsurg.2007.06.024, 18361927.
4. Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 2002, 53:810-821. 10.1016/S0360-3016(02)02846-8, 12095546.
5. Ikai I, Arii S, Okazaki M, Okita K, Omata M, Kojiro M, Takayasu K, Nakanuma Y, Makuuchi M, Matsuyama Y, Monden M, Kudo M. Report of the 18th follow-up survey of primary liver cancer in Japan. Hepatol Res 2010, 40:1043-1059.
6. Rhim H, Lim HK. Radiofrequency ablation for hepatocellular carcinoma abutting the diaphragm: the value of artificial ascites. Abdom Imaging 2009, 34:371-380. 10.1007/s00261-008-9408-4, 18463915.
7. Torzilli G, Makuuchi M, Inoue K, Takayama T, Sakamoto Y, Sugawara Y, Kubota K, Zucchi A. No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients: is there a way? A prospective analysis of our approach. Arch Surg 1999, 134:984-992. 10.1001/archsurg.134.9.984, 10487594.
8. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005, 54:1151-1156. 10.1136/gut.2004.045203, 1774888, 16009687.
9. Yamashita H, Nakagawa K, Shiraishi K, Tago M, Igaki H, Nakamura N, Sasano N, Shiina S, Omata M, Ohtomo K. External beam radiotherapy to treat intra- and extra-hepatic dissemination of hepatocellular carcinoma after radiofrequency thermal ablation. J Gastroenterol Hepatol 2006, 21:1555-1560. 10.1111/j.1440-1746.2006.04432.x, 16928216.
10. Herfarth KK, Debus J, Lohr F, Bahner ML, Rhein B, Fritz P, Höss A, Schlegel W, Wannenmacher MF. Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol 2001, 19(1):164-170.
11. Wada H, Takai Y, Nemoto K, Yamada S. Univariate analysis of factors correlated with tumor control probability of three-dimensional conformal hypofractionated high-dose radiotherapy for small pulmonary or hepatic tumors. Int J Radiat Oncol Biol Phys 2004, 58(4):1114-1120. 10.1016/j.ijrobp.2003.08.012, 15001252.
12. Kavanagh BD, Schefter TE, Cardenes HR, Stieber VW, Raben D, Timmerman RD, McCarter MD, Burri S, Nedzi LA, Sawyer TE, Gaspar LE. Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol 2006, 45(7):848-855. 10.1080/02841860600904870, 16982549.
13. Hoyer M, Roed H, Traberg Hansen A, Ohlhuis L, Petersen J, Nellemann H, Kiil Berthelsen A, Grau C, Aage Engelholm S, Von der Maase H. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 2006, 45(7):823-830. 10.1080/02841860600904854, 16982546.
14. Katz AW, Carey-Sampson M, Muhs AG, Milano MT, Schell MC, Okunieff P. Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol Biol Phys 2007, 67(3):793-798. 10.1016/j.ijrobp.2006.10.025, 17197128.
15. Goodman KA, Wiegner EA, Maturen KE, Zhang Z, Mo Q, Yang G, Gibbs IC, Fisher GA, Koong AC. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys 2010, 78(2):486-493. 10.1016/j.ijrobp.2009.08.020, 20350791.
16. Lee MT, Kim JJ, Dinniwell R, Brierley J, Lockwood G, Wong R, Cummings B, Ringash J, Tse RV, Knox JJ, Dawson LA. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 2009, 27:1585-1591. 10.1200/JCO.2008.20.0600, 19255313.
17. Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, Franklin W, Kane M, Gaspar LE, Schefter TE. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009, 27:1572-1578. 10.1200/JCO.2008.19.6329, 19255321.
18. Rule W, Timmerman R, Tong L, Abdulrahman R, Meyer J, Boike T, Schwarz RE, Weatherall P, Chinsoo Cho L. Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol 2011, 18:1081-1087. 10.1245/s10434-010-1405-5, 21046264.
19. Chang DT, Swaminath A, Kozak M, Weintraub J, Koong AC, Kim J, Dinniwell R, Brierley J, Kavanagh BD, Dawson LA, Schefter TE. Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer 2011, 117:4060-4069. 10.1002/cncr.25997, 21432842.
20. Fumagalli I, Bibault JE, Dewas S, Kramar A, Mirabel X, Prevost B, Lacornerie T, Jerraya H, Lartigau E. A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases. Radiat Oncol 2012, 7:164. 10.1186/1748-717X-7-164, 3494573, 23014094.
21. Takeda A, Kunieda E, Ohashi T, Aoki Y, Koike N, Takeda T. Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. Radiother Oncol 2011, 101(2):255-259. 10.1016/j.radonc.2011.05.033, 21641064.
22. Murakami T, Imai Y, Okada M, Hyodo T, Lee WJ, Kim MJ, Kim T, Choi BI. Ultrasonography, computed tomography and magnetic resonance imaging of hepatocellular carcinoma: toward improved treatment decisions. Oncology 2011, 81(Suppl 1):86-99.
23. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011, 53:1020-1022. 10.1002/hep.24199, 3084991, 21374666.
24. European association for the study of the liver; European organisation for research and treatment of cancer EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012, 56:908-943. European association for the study of the liver; European organisation for research and treatment of cancer.
25. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010, 30:52-60. 10.1055/s-0030-1247132, 20175033.
26. Tse RV, Hawkins M, Lockwood G, Kim JJ, Cummings B, Knox J, Sherman M, Dawson LA. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008, 26:657-664. 10.1200/JCO.2007.14.3529, 18172187.
27. Chi A, Liao Z, Nguyen NP, Xu J, Stea B, Komaki R. Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications. Radiother Oncol 2010, 94:1-11. 10.1016/j.radonc.2009.12.008, 20074823.
28. Andolino DL, Johnson CS, Maluccio M, Kwo P, Tector AJ, Zook J, Johnstone PA, Cardenes HR. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2011, 81:e447-e453. 10.1016/j.ijrobp.2011.04.011, 21645977.
29. Kang JK, Kim MS, Cho CK, Yang KM, Yoo HJ, Kim JH, Bae SH, Jung da H, Kim KB, Lee DH, Han CJ, Kim J, Park SC, Kim YH. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer 2012, 118:5424-5431. 10.1002/cncr.27533, 22570179.
30. Blomgren H, Lax I, Näslund I, Svanström R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol 1995, 34:861-870. 10.3109/02841869509127197, 7576756.
31. Cardenes HR, Price TR, Perkins SM, Maluccio M, Kwo P, Breen TE, Henderson MA, Schefter TE, Tudor K, Deluca J, Johnstone PA. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol 2010, 12:218-225. 10.1007/s12094-010-0492-x, 20231127.
32. Kwon JH, Bae SH, Kim JY, Choi BO, Jang HS, Jang JW, Choi JY, Yoon SK, Chung KW. Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer 2010, 10:475. 10.1186/1471-2407-10-475, 2940809, 20813065.
33. Louis C, Dewas S, Mirabel X, Lacornerie T, Adenis A, Bonodeau F, Lartigau E. Stereotactic radiotherapy of hepatocellular carcinoma: preliminary results. Technol Cancer Res Treat 2010, 9:479-487.
34. Seo YS, Kim MS, Yoo SY, Cho CK, Choi CW, Kim JH, Han CJ, Park SC, Lee BH, Kim YH, Lee DH. Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma. J Surg Oncol 2010, 102:209-214. 10.1002/jso.21593, 20740576.
35. Goyal K, Einstein D, Yao M, Kunos C, Barton F, Singh D, Siegel C, Stulberg J, Sanabria J. Cyberknife stereotactic body radiation therapy for nonresectable tumors of the liver: preliminary results. HPB Surg 2010, 2010. doi: 10.1155/2010/309780.
36. Son SH, Choi BO, Ryu MR, Kang YN, Jang JS, Bae SH, Yoon SK, Choi IB, Kang KM, Jang HS. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication. Int J Radiat Oncol Biol Phys 2010, 78:1073-1080. 10.1016/j.ijrobp.2009.09.009, 20207492.
37. Dawood O, Mahadevan A, Goodman KA. Stereotactic body radiation therapy for liver metastases. Eur J Cancer 2009, 45:2947-2959. 10.1016/j.ejca.2009.08.011, 19773153.
38. van Laarhoven HW, Kaanders JH, Lok J, Peeters WJ, Rijken PF, Wiering B, Ruers TJ, Punt CJ, Heerschap A, van der Kogel AJ. Hypoxia in relation to vasculature and proliferation in liver metastases in patients with colorectal cancer. Int J Radiat Oncol Biol Phys 2006, 64:473-482. 10.1016/j.ijrobp.2005.07.982, 16242253.
39. McCammon R, Schefter TE, Gaspar LE, Zaemisch R, Gravdahl D, Kavanagh B. Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2009, 73:112-118. 10.1016/j.ijrobp.2008.03.062, 18786780.
40. Takeda A, Sanuki N, Eriguchi T, Kobayashi T, Iwabutchi S, Matsunaga K, Mizuno T, Yashiro K, Nisimura S, Kunieda E. Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma. J Gastroenterol Hepatol 2013, 29:372-379.